Strides Pharma Science Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 29,670.89 million compared to INR 27,020.17 million a year ago. Revenue was INR 30,203.36 million compared to INR 27,652.24 million a year ago. Net loss was INR 887.89 million compared to INR 1,930.93 million a year ago. Basic loss per share from continuing operations was INR 15.76 compared to INR 23.52 a year ago. Diluted loss per share from continuing operations was INR 15.76 compared to INR 23.52 a year ago. Basic loss per share was INR 9.79 compared to INR 21.45 a year ago. Diluted loss per share was INR 9.79 compared to INR 21.45 a year ago.